These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2714074)

  • 41. Desacetylcefotaxime--another broad spectrum cephalosporin?
    Fuchs PC; Jones RN; Barry AL; Allen SD; Ayers LW; Pfaller M
    J Antimicrob Chemother; 1989 Jan; 23(1):165-7. PubMed ID: 2745252
    [No Abstract]   [Full Text] [Related]  

  • 42. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
    Devlin HR; Boskovski L
    Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The in vitro antimicrobial activity of desacetylcefotaxime compared to other related beta-lactams.
    Schrinner E; Limbert M; Seeger K; Seibert G; Novick WJ
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):13S-20S. PubMed ID: 6086214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the young.
    Kearns GL; Young RA
    Diagn Microbiol Infect Dis; 1995; 22(1-2):97-104. PubMed ID: 7587057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symposium: new findings on the antibacterial interactions between cefotaxime and desacetylcefotaxime.
    Diagn Microbiol Infect Dis; 1989; 12(1):23-121. PubMed ID: 2714069
    [No Abstract]   [Full Text] [Related]  

  • 46. Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.
    Marone P; Navarra A; Monzillo V; Traverso A
    Drugs Exp Clin Res; 1990; 16(12):629-33. PubMed ID: 2130005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The activity of cefotaxime and desacetylcefotaxime against Bacteroides species compared to 7-methoxy cephems and other anti-anaerobe drugs.
    Jones RN
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():39-43. PubMed ID: 6094461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut.
    Freeman J; O'Neill FJ; Wilcox MH
    J Antimicrob Chemother; 2003 Jul; 52(1):96-102. PubMed ID: 12775682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative determination of cefotaxime and desacetyl cefotaxime in serum and bile by bioassay and high-performance liquid chromatography.
    Kees F; Strehl E; Seeger K; Seidel G; Dominiak P; Grobecker H
    Arzneimittelforschung; 1981; 31(2):362-5. PubMed ID: 6261772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [In vitro evaluation of the activity and interactions of cefotaxime and its metabolite desacetylcefotaxime against strains of enterobacteria, staphylococci and Bacteroides fragilis isolated from hospital infections].
    Pitzus E
    G Ital Chemioter; 1989; 36(1-3):57-64. PubMed ID: 2488914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Influence of antibiotic disk charge on concordance curve of cefotaxime ].
    Drugeon HB; Seon M; Reynaud A; Chung SS; Courtieu AL
    Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):517-21. PubMed ID: 6289229
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefotaxime stability during in vitro microbiological testing.
    Marchbanks CR; Yost RL; White RL
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1375-8. PubMed ID: 3314698
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Sensitivity of the recent bacterial isolates to cefotaxime and other cephem antibiotics].
    Fujita S; Yoshida T; Okado N; Matsubara F
    Jpn J Antibiot; 1983 Oct; 36(10):2887-92. PubMed ID: 6325747
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative in vitro studies on cefotaxime and desacetylcefotaxime.
    Selwyn S; Bakhtiar M
    Drugs Exp Clin Res; 1986; 12(12):953-65. PubMed ID: 3494587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Biliary excretion of cefotaxime and desacetylcefotaxime].
    Jehl F; Peter JD; Picard A; Dupeyron JP; Marescaux J; Sibilly A; Monteil H
    Rev Med Interne; 1987; 8(5):487-92. PubMed ID: 3445030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.
    Jones RN; Barry AL; Thornsberry C
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):345-9. PubMed ID: 3698547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.
    Sjölin J; Eriksson N; Arneborn P; Cars O
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2606-10. PubMed ID: 1810195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.